VACCINE FOR CTL IMMUNITY TO HUMAN IMMUNODEFICIENCY VIRUS

这个项目的目标是开发方法， 细胞毒性T淋巴细胞（CTL）对人类免疫缺陷病毒的免疫， 使用非活疫苗的其他病原体。 目前，最佳方法 并不存在来引发这种对病毒的关键免疫形式。 的 开发针对这些病原体的有效疫苗将是非常重要的。 对人和动物都有好处。 目前正在采取两种新的办法。 第一种方法将通过利用肽来引发CTL。 观察到肽与I类主要组织相容性相关 β 2-微球蛋白重新结合后的复合物（MHC）分子。 将开发用于引入肽的方法， β 2-微球蛋白在体内形成I类肽 MHC分子复合物和主要CTL。 第二种方法将 CTL的完整蛋白质，利用观察到， 抗原可以通过一种专门的抗原呈递蛋白呈递给CTL 正常组织中的细胞。 我们将开发合适的方法， 增强抗原进入该抗原呈递途径。 这些 将开发与鼠相关的疫苗方法， 然后是人类I类MHC分子。

The goal of this project is to develop methodology to prime cytotoxic T lymphocyte (CTL) immunity to Human Immunodeficiency Virus and other pathogens using nonliving vaccines. Currently, optimal methods do not exist to prime this critical form of immunity to viruses. The development of efficacious vaccines to these pathogens would be of great benefit to both man and animals. Two novel approaches are being taken. The first approach will prime CTL's with peptides by exploiting the observation that peptides associate with class I Major Histocompatibility Complex (MHC) molecules upon reassociation of beta2-microglobulin. Methods will be developed for introducing peptides and beta2-microglobulin in-vivo in a manner that will form peptide-class I MHC molecule complexes and prime CTL's. The second approach will prime CTL's with intact proteins by exploiting the observation that native antigens can be presented to CTL's by a specialized antigen-presenting cell resident in normal tissues. We will develop suitable methods for enhancing antigen entry into this pathway of antigen-presentation. These approaches will be developed for vaccines in association with murine, and then human class I MHC molecules.